GI
CRSP icon

GAMMA Investing’s CRISPR Therapeutics CRSP Stock Holding History

GAMMA Investing’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$68.9K Buy
1,246
+597
+92% +$32.2K ﹤0.01% 2144
2026
Q2 		$35.4K Buy
649
+36
+6% +$1.9K ﹤0.01% 2533
2026
Q1 		$29.2K Buy
613
+247
+67% +$13K ﹤0.01% 2515
2025
Q4 		$19.2K Buy
366
+84
+30% +$5.03K ﹤0.01% 2642
2025
Q3 		$18.3K Buy
+282
New +$16.2K ﹤0.01% 2559
2025
Q2 		– Sell
-126
Closed -$4.29K – 3795
2025
Q1 		$4.29K Buy
126
+74
+142% +$3.14K ﹤0.01% 3143
2024
Q4 		$2.05K Sell
52
-6
-10% -$283 ﹤0.01% 3210
2024
Q3 		$2.73K Buy
58
+3
+5% +$152 ﹤0.01% 2967
2024
Q2 		$2.97K Buy
55
+5
+10% +$289 ﹤0.01% 2754
2024
Q1 		$3.41K Buy
50
+20
+67% +$1.43K ﹤0.01% 2562
2023
Q4 		$1.89K Buy
+30
New +$1.66K ﹤0.01% 2594

Other funds holding CRSP

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $937M AUM 18.56% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
HPBT
Hickory Point Bank & Trust Decatur, Illinois $166M AUM 19.36% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

GAMMA Investing's CRSP Position: Q3 2026 in Review

GAMMA Investing increased its CRISPR Therapeutics (CRSP) stake by 92% in Q3 2026, buying an estimated $32.2K and bringing the position to 1,246 shares worth $68.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2144.

GAMMA Investing first reported a position in CRSP in Q4 2023 and has held it in 11 quarters since. 13 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • GAMMA Investing held 1,246 shares of CRISPR Therapeutics worth $68.9K as of Q3 2026.
  • GAMMA Investing bought 597 CRISPR Therapeutics shares in Q3 2026, an estimated $32.2K.
  • CRISPR Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2144 holding.
  • GAMMA Investing first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 13 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.